747353-31-7

Basic information

• Product Name: Benzenamine, 2,6-diethyl-N-2-imidazolidinylidene- (9CI)
• Synonyms: Benzenamine, 2,6-diethyl-N-2-imidazolidinylidene- (9CI)
• CAS NO: 747353-31-7
• Molecular Formula: C13H19N3
• Molecular Weight: 217.31006
• Product Categories: ETHYL
• Mol File: 747353-31-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenamine, 2,6-diethyl-N-2-imidazolidinylidene- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2,6-diethyl-N-2-imidazolidinylidene- (9CI)(747353-31-7)
• EPA Substance Registry System: Benzenamine, 2,6-diethyl-N-2-imidazolidinylidene- (9CI)(747353-31-7)

Safety Data

• Hazardous Substances Data: 747353-31-7(Hazardous Substances Data)

Upstream product

• 5391-39-9 1-acetylimidazolidin-2-one 
• 579-66-8 2,6-diethylaniline 
• 86861-31-6 1-acetyl-N-(2,6-diethylphenyl)-4,5-dihydro-1H-imidazol-2(3H)-imine 

Relevant articles and documents

Three-dimensional pharmacophore hypotheses of octopamine/tyramine agonists which inhibit [1-14C]acetate incorporation in Plodia interpunctella

Three-dimensional pharmacophore hypotheses were built from a set of 36 octopamine (OA)/tyramine (TA) agonists responsible for the inhibition of sex-pheromone production in Plodia interpunctella. Among the ten chemical-featured models generated by a program Catalyst/Hypo, hypotheses including hydrogen-bond acceptor (HBA), hydrogen-bond acceptor aliphatic (HBAl), hydrophobic (Hp), hydrophobic aromatic (HpAr) and hydrophobic aliphatic (HpAl) features were considered to be important and predictive in evaluating OA/TA agonists. Active agonists mapped well onto all the features of the hypothesis such as HBA, HBAl, Hp, HpAr and HpAl features. On the other hand, inactive compounds were shown to be poorly capable of achieving an energetically favorable conformation shared by the active molecules in order to fit the 3-D chemical-feature pharmacophore models. Those hypotheses are considered to be used in designing new leads for hopefully more active compounds. Further research on the comparison of models from the agonists may help elucidate the mechanisms of OA/TA receptor-ligand interactions.

TREATMENT OF URINARY INCONTINENCE BY ADMINISTRATION OF ALPHA 1L-ADRENOCEPTOR AGONISTS

The present invention relates to the use of α lL-agonists for treating urinary incontinence.

Method of lowering intraocular pressure using phenylimino-imidazoles

A method is provided of treating glaucoma in a patient which comprises administering, preferably as eye drops, an effective amount of the compound STR1 which is preferably in the form of its hydrochloride. The compound is administered preferably in the form of a sterile pharmacologically acceptable solution which contains from 0.1 to 5, and more preferably 0.1 to 2.0, percent by weight of said compound. The patient preferably obtains the anti-glaucoma agent in the form of a kit which comprises the sterile pharmacologically acceptable solution and an eyedropper for dispensing said sterile pharmacologically acceptable solution to the affected eyes of a patient suffering from glaucoma.